Table 9.
ABG | p-Value | Placebo | p-Value | P for Difference * | |
---|---|---|---|---|---|
Energy, kcal/day Baseline 6 weeks |
2031 ± 579 | 2004 ± 665 0.734 |
1950 ± 543 2015 ± 560 |
0.321 | 0.381 |
CHO, % energy Baseline 6 weeks |
37.1 ± 8.7 36.7 ± 8.8 |
0.628 | 36.9 ± 6.8 36.0 ± 6.4 |
0.251 | 0.687 |
CHO, grams Baseline 6 weeks |
186 ± 62 188 ± 83 |
0.822 | 179 ± 54 179 ± 53 |
0.995 | 0.854 |
Protein, % energy Baseline 6 weeks |
16.7 ± 3.2 16.9 ± 4.7 |
0.759 | 17.0 ± 4.3 17.0 ± 2.9 |
0.930 | 0.864 |
Protein, grams Baseline 6 weeks |
81.9 ± 23.9 82.3 ± 27.3 |
0.895 | 79.0 ± 24.2 | 84.2 ± 22.8 0.080 |
0.225 |
Total fat, % energy Baseline 6 weeks |
41.8 ± 6.8 41.5 ± 7.0 |
0.769 | 41.8 ± 6.5 43.9 ± 7.3 |
0.030 | 0.102 |
Total fat, grams Baseline 6 weeks |
96.9 ± 34.6 95.7 ± 39.3 |
0.818 | 96.3 ± 40.3 97.8 ± 34.3 |
0.446 | 0.776 |
SFA, % energy Baseline 6 weeks |
11.9 ± 3.8 11.8 ± 3.4 |
0.793 | 12.0 ± 3.5 12.1 ± 3.2 |
0.831 | 0.716 |
SFA, grams Baseline 6 weeks |
27.5 ± 11.8 27.7 ± 14.1 |
0.945 | 26.9 ± 13.0 28.1 ± 12.7 |
0.451 | 0.697 |
MUFA, % energy Baseline 6 weeks |
23.4 ± 6.8 19.0 ± 5.0 |
<0.001 | 23.8 ± 5.7 20.2 ± 3.6 |
<0.001 | 0.463 |
MUFA, grams Baseline 6 weeks |
55.1 ± 24.5 44.0 ± 19.2 |
0.003 | 52.1 ± 20.8 45.6 ± 15.2 |
0.010 | 0.324 |
PUFA, % energy Baseline 6 weeks |
7.6 ± 2.1 7.1 ± 1.9 |
0.142 | 7.7 ± 2.3 7.0 ± 2.2 |
0.029 | 0.699 |
PUFA, grams Baseline 6 weeks |
17.8 ± 8.0 16.0 ± 7.0 |
0.114 | 16.9 ± 7.3 16.4 ± 8.7 |
0.680 | 0.443 |
Fiber, g/day | |||||
Baseline 6 weeks |
20.2 ± 9.2 20.3 ± 9.6 |
0.958 | 20.4 ± 11.3 19.6 ± 8.0 |
0.259 | 0.606 |
Alcohol, g/day Baseline 6 weeks |
5.8 (2.2–13.3) 5.3 (1.2–14.0) |
0.866 | 8.2 (1.1–17.5) 7.9 (0.00–17.8) |
0.507 | 0.947 |
ABG, aged black garlic; CHOs, carbohydrates; SFAs, saturated fatty acids; MUFAs, monounsaturated fatty acids; PUFAs, polyunsaturated fatty acids. Data are expressed as the mean ± standard deviation; median (25–75th percentile). Intra-treatment comparisons by Student’s t-test and Wilcoxon test for related samples. * p-Value for differences among treatments. ANOVA and Wilcoxon tests.